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Individualized treatment regimens may reduce patient burden with satisfactory patient outcomes in neovascular age-related
macular degeneration. Intravitreal anti-VEGF drugs are the current gold standard. Fixed monthly injections offer the best visual
outcome but this regimen is not commonly followed outside clinical trials. A PRN regimen requires monthly visits where the
patient is treated in the presence of signs of lesion activity.Therefore, an early detection of reactivation of the disease with immediate
retreatment is crucial to prevent visual acuity loss. Several trials suggest that “treat and extend” and other proactive regimens provide
a reasonable approach. The rationale of the proactive regimens is to perform treatment anticipating relapses or recurrences and
therefore avoid drops in vision while individualizing patient followup. Treat and extend study results in significant direct medical
cost savings from fewer treatments and office visits compared to monthly treatment. Current data suggest that, for one year, PRN is
less expensive, but treat and extend regimen would likely be less expensive for subsequent years. Once a patient is not a candidate
to continue with treatment, he/she should be sent to an outpatient unit with adequate resources to follow nAMD patients in order
to reduce the burden of specialized ophthalmologist services.
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1. Early Diagnosis and Treatment Initiation
Age-related macular degeneration (AMD) is the leading
cause of blindness among the elderly in the Western world
[1–3]. Currently, there is no cure for the disease; however,
intravitreal antivascular endothelial growth factor (anti-
VEGF) agents have significantly improved visual outcomes in
patients with neovascular age-related macular degeneration
(nAMD) [4–7].These new therapeutic approaches have been
shown to prevent and in some cases reverse visual damage
caused by nAMD in clinical trials. Early diagnosis is obvi-
ously essential in order to take action as promptly as possible
to obtain the best result from therapy [8]. Therefore, primary
care physicianswho suspect nAMDshould directly refer their
patients to an ophthalmologist [9]. It is advisable to establish
a referral protocol based on signs and symptoms in order to
maximize efficiency and utilization of health resources.
Based on clinical evidence, most protocols recommend
administering three consecutive monthly intravitreal injec-
tions of ranibizumab [8, 10, 11]. The pivotal studies MARINA
[4] and ANCHOR [5] and later Pronto [12], SUSTAIN [13],
and IVAN [14] scheduled three loading doses of ranibizumab
as initial treatment. Their results have shown that visual acu-
ity (VA) improves plateaus after the first three injections.The
current summary of product characteristics of ranibizumab
recommends initiating the treatment with a loading phase
consisting of a monthly injection of 0.5mg ranibizumab dur-
ing three consecutivemonths. However, more recently CATT
[6] protocol found that after the first year ranibizumab given
as needed without the use of three mandatory loading doses
was equivalent to ranibizumab given monthly. Therefore,
althoughmost clinical protocols recommend a loading phase,
we still do not have conclusive data to support the superiority
of three mandatory monthly initial doses over one dose.
These results have also been endorsed recently with the
use of aflibercept in the VIEW-1 and VIEW-2 studies which
have established its indication for the treatment of nAMD
with a recommended regimen of 2mg injection every 8
weeks during the first year following a loading phase of three
injections [7].
Furthermore, the response to the initial loading dose
constitutes a very important parameter to assess the possible
progression of the patient, to establish a profile for future
response to treatment, and to individualize the therapy [15,
16]. Thus, following the loading dose in the SUSTAIN study,
53% maintain what was gained in the first three months, 21%
do not maintain it, and 26% did not gain vision [13].
As far as bevacizumab is concerned, some studies also
recommend a loading dose [17, 18], but in CATT study, the
comparison between bevacizumab given as needed without
loading phase and bevacizumab givenmonthly was inconclu-
sive, so neither no inferiority nor inferiority was established
between the two study groups [6].
2. Individualized Treatment Protocols
Intravitreal ranibizumab based on a PRN (Pro Re Nata or “as
needed”) regimen where retreatment is given in the presence
of signs of activity is frequently used for the management
of neovascular age-related macular degeneration. However,
strict monthly monitoring is required to obtain the best
results. This represents a huge burden for both the ophthal-
mologist and the patient, though some patients do not need
to be monitored monthly. Individualization of the treatment
and followup is a key to ensure optimal clinical outcomes for
those patients.
In the pivotalMARINA andANCHOR trials, ranibizumab
was administered monthly for two years in patients with
nAMD.With this treatment protocol, mean VA improved 6.6
letters and 10.7 letters, respectively [4, 5]. In the VIEW trials,
bimonthly aflibercept 2.0mg showed very similar visual
results compared to monthly ranibizumab 0.5mg [7].
The Pronto study pioneered retreatment based on optical
coherence tomography (OCT) findings. In this study, 40
patients were monitored monthly after receiving a loading
dose of three consecutive ranibizumab injections. Retreat-
ment was mainly administered in the presence of VA loss
and persistent or recurrent intraretinal or subretinal fluid
on OCT scans. At 24 months, mean VA improved 11 letters
and 43% of patients gained 15 or more letters, with an
average of 9.9 injections [12]. However, the promising results
of the Pronto study could not be reproduced in the larger
SUSTAIN trial with a similar treatment regimen [13]. These
studies laid the foundations of the so-called PRN regimen.
Notwithstanding, strict monthly monitoring is required to
achieve a good clinical outcome with no tolerance to the
presence of macular fluid detected on OCT, which has been
demonstrated in the CATT trial [6]. The CATT study con-
cluded that ranibizumab and bevacizumab were equivalent
in terms of VA results when given under the same treatment
protocol; however, ranibizumab better corrected anatomic
pathologies as demonstrated by OCT. At two years, monthly
injections of each treatment were found to be superior to
their respective PRN regimens. Importantly, this study has
also shown that patients receiving monthly injections with
either ranibizumab or bevacizumab during the first year who
are then rerandomized to PRN treatment during the second
year had similar VA results as patients treated with a PRN
regimen from the start. Therefore, an aggressive approach at
the beginning of the disease does not seem to be a key factor
for a better long-term outcome.
It seems that the key to the success ofmonthly dosingmay
possibly lie in treating before further disease progression,
that is, treatment being administered even when the lesion is
inactive. In this approach, the treatment has the advantage—
not the disease. If this theory was correct, the ideal treatment
would be one that anticipates and prevents disease but at
the same time avoids the burden and risks of the monthly
injections. The proactive regimens such as treat and extend
or the Fusion regimens seek this goal.
In the “inject and extend” or “treat and extend” regimens,
the intervals between reinjections are progressively extended
if there is no fluid, thereby “titrating” a patient’s individual
maximal treatment-free interval [19, 20]. The visual results
of these regimens gave satisfactory results. The 1-year results
of the LUCAS trial, the largest and best performed treat
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and extend study, showed equivalent effectiveness in the VA
scores with ranibizumab (8.2 letters) and bevacizumab (8
letters). These results were achieved with a mean of eight
injections in the ranibizumab group and a mean of 8.8
injections in the bevacizumab group. The difference in the
number of injections reached significance (𝑃 = 0.002) [19].
In addition, a small retrospective nonrandomized case series
showed more favourable results with the treat and extend
regimen than with PRN, probably because patients in the
PRN group were only examined 8.8 times a year instead
of the 12 times initially expected [20]. According to the
ASRS PAT survey, treat and extend regimen is preferred by
most physicians (communication at the American Academy
Meeting in New Orleans, November 2013). In the treat and
extend regimen, the patients are treated regardless of the
presence of fluid or neovascular activity. In the absence of
neovascular activity, the patient receives the treatment at
each visit; however, the interval between subsequent visits
will continually be extended several weeks unless disease
activity returns. In this manner, the treatment anticipates
and avoids the relapses. In the case of the PRN regimen, the
treatment tries to catch up to the relapses but has no chance by
definition to prevent them. Randomized prospective studies
comparing the two methods are now needed to establish the
best reinjection strategy for patients treated with anti-VEGF
drugs, as the one currently in progress sponsored by the
Spanish Vitreoretinal Society (In Eye study, EudraCT number
2012-003431-37).
The Fusion regimen combines the PRN approach with
fixed injections after certain periods of (apparent) inactivity
[21, 22]. In the second year of the VIEW study, a similar
approach was followed and was termed capped-PRN [7].
The Fusion regimen consists of three steps. First, a loading
phase of three consecutive monthly injections is given. If
CNV activity is resolved at the first follow-up visit, the
loading phase can be reduced to two monthly injections.
Second, a PRN regimen is established on demand, and
intravitreal injections are given if CNV activity is present.
After cessation of CNV activity, patients still receive one
injection. Third, after cessation of CNV activity, patients
receive fixed injections every 2 months for two courses and
every 3 months for two courses. At the intermediate visits,
between the preplanned fixed injections, patients are treated
according to PRN criteria [22].
Though conceptually different, the Fusion regimen has
some similarities with the proposed “treat and extend” reg-
imen [23, 24] because both regimens aim at the prevention of
disease recurrence. The main differences between the Fusion
and “treat and extend” regimens are that in the latter the peri-
ods between treatments are extended in a continuous linear
form and that there are no visits in between these periods.
In summary, the rationale of the proactive regimens is to
perform treatment anticipating the relapses or recurrences
and therefore avoid drops in vision while individualizing
patient followup. The objective is to avoid irreversible loss
of vision at recurrences despite reactive treatment. Proactive
regimens not only reduce the number of injections and
their associated risks as do PRN regimens but also minimize
the number of visits and their associated costs and inconve-
nience. Treat and extend has the potential to be most cost-
effective regimen, by reducing the frequency of injections
compared tomonthly regimen, as well as the number of visits
compared to PRN. Due to the proactivity of the treatment,
this reduced cost does not compromise clinical benefit or
efficacy.
The main weakness so far is that these regimens have not
yet been validated in larger, controlled, randomized trials.
3. Socioeconomical Burden
Different challengesmust be faced in the long-term treatment
of nAMD with intravitreal injections of ranibizumab. One
of the major problems is how to manage a high number of
patients who require frequent monitoring visits and retreat-
ments. It is known that monthly visits are mandatory during
the initial period after the onset of the disease to optimize
the results that can be obtained with the treatment. However,
these follow-up visits can be progressively extended if the
lesion remains stable. Currently, there is lack of evidence
to recommend a “treat and extend” regimen instead of a
PRN regimen. The percentage of patients gaining 15 or more
letters and the mean VA change are not as good in studies
performed in a “real-world” context as in clinical trials. This
could be due to the wide range of lesions treated in clinical
practice compared to the strictly selected ones in randomized
trials. Furthermore, although flexible regimens may reduce
the burden of visits and injections, they might offer a less
favourable long-term outcome.
The goal of OCT-driven treatment protocols is to achieve
a “dry macula” with repeated injections. Nevertheless, some
residual fluid may be left untreated if VA is stable during
several follow-up visits. This might be relevant to save some
extra injections making the treatment more cost-effective.
4. Signs of Activity and Retreatment Criteria in
Individualized Therapies
Initially, it should be established that there is no structural
damage defined as longstanding fibrosis or atrophy in the
foveal area, significant chronic disciform scar, or other severe
ocular diseases like vitreous hemorrhage or rhegmatogenous
retinal detachment. It is also recommended that treatment
with ranibizumab should not be commenced if there is
evidence or suspicion of hypersensitivity to this drug [11].
The choroidal neovascular membrane should be con-
sidered active if it presents any of the following features:
abnormal retinal thickness, particularly if there is evidence
of accumulated intraretinal or subretinal fluid, or fluid
under the RPE, confirmed by OCT; presence or recurrence
of intraretinal fluid and/or subretinal fluid or subretinal
hemorrhage; new or persistent leakage detected with angiog-
raphy fluorescein; choroidal neovascular membrane growth
detected with angiography fluorescein; and VA deterioration,
considered to represent deterioration of the choroidal neo-
vascular membrane [25].
Choroidal neovascular membrane disease progression is
defined by the Institute for Health and Clinical Excellence
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[26] as the appearance of sight-threatening choroidal neo-
vascular membrane which was not previously suspected or
thought to be present or evidence of new hemorrhage and/or
subretinal fluid or a documented recent visual decline in the
choroidal neovascular membrane or an increase in the lesion
size between visits.
The disease should be considered to have become inactive
when there is [11] persistence or absence of fluid with absence
of fluorescein leakage or other signs of disease activity like
increasing lesion size, new haemorrhages, or exudates; no
deterioration in vision that can be attributed to choroidal
neovascular membrane activity; no lesion growth or new
signs of disease activity on subsequent followup following
recent discontinuation of treatment; and no worsening of
OCT indicators of choroidal neovascular membrane disease.
Retreatment criteria from Pronto study [12] are defined
if any of the following changes were observed: VA loss of
at least 5 letters or 1 EDTRS line; an increase in OCT of at
least 100m; new macular hemorrhage; new area of classic
neovascular choroidal membrane; or evidence of persistent
fluid on OCT one month after injection. Detachment of
pigment epithelium was recorded as an OCT finding but was
not included as retreatment criteria. This decision was based
on the observations from phase I/II extension Pronto study
with ranibizumab. In this study, little correlation between
the presence of pigment epithelium detachment and VA was
observed. During the second year of the study, retreatment
criteria were changed to include any qualitativemodifications
in the OCT that suggested fluid in the macular area. These
changes included the appearance of retinal cysts or subretinal
fluid or an enlargement of the pigment epithelium detach-
ment. Any of these qualitative changes alone was sufficient to
permit retreatment [12].
In the SUSTAIN [13] study, retreatment was based on VA
and OCT findings indicating loss of more than five letters
of VA from the previous highest VA score and OCT criteria
≥100m increase from the previous lowest measurement.
It is important to remember that some degenerative
retinal changes observed with OCT can be presented as
hyporeflective images and may not correspond to fluid but
structural changes like the residual internal layers pseudo-
cysts or the outer retinal tabulations [27]. In these cases we
must rule out the possibility that the fluid is not representing
disease activity.
5. Nonresponder and Therapeutical Approach
There is not an accepted definition of nonresponders to nAMD
treatment. However, in clinical practice, some patients do
not respond adequately to the treatment. Even with monthly
injections of ranibizumab at the 2-year followup, 9% of the
patients in the MARINA study and 10% of patients in the
ANCHOR study lost more than 15 letters of VA [28]. Patients
with good VA at baseline might have difficulty improving 3
lines of VA compared with the greater likelihood of losing
3 lines of VA. The opposite is likely true for patients with
poor VA at baseline. It may be impossible for a patient with
poor VA at baseline to lose an additional 3 lines of VA,
whereas there is a greater likelihood of improving 3 lines
once treatment is initiated [28]. If vision loss is associated
with a suppressed CNV without leakage but is associated
with pigmentary abnormalities and geography atrophic scar,
it does not seem that a shift to another treatment would allow
any improvement.
In addition, the failure of anti-VEGF monotherapy to
provide a long-lasting resolution of intraretinal or subretinal
fluid is frequently observed even in clinical trials. In the
CATT study, the proportion of patients without fluid onOCT
in the ranibizumabmonthly group,where the best anatomical
results were obtained, was 45.5% after two years of followup
[6].
Therefore, both functional and anatomical aspects must
be considered when we define a nonresponder, and we
must consider both the short time and the long time after
beginning the treatment, in order to decide the management
of these patients.
In the short term, the SUSTAIN study identified three
groups of responders to ranibizumab therapy after the
loading doses [13]: those who gained vision (one or more
letters) in the initial 3 months and maintained that vision
in the maintenance phase (53%); those who gained vision
in the initial 3 months but did not maintain it through the
maintenance phase and stabilized at the baseline VA level
(21%); and those who had no initial vision gain and no gain
during the PRN phase. In that group, rather a decrease in
BCVA was observed during the follow-up period (26%). In
this third group, if VA gets worse and fluid is still present in
the OCT, we can consider the patient a “real nonresponder.”
If the patient has a bad VA and a disciform scar, probably no
additional treatment should be provided, although this can
be reconsidered if it is the eye with the best VA of the patient.
If the patient has still a useful vision, additional tests
should be used to determine different macular diseases
that should be treated in a different way. Diagnosis of
polypoidal choroidal vasculopathy (PCV) should be based
on early phase hyperfluorescent hot spots visualized using
indocyanine green angiography (ICG). Treatment of PCV
is usually performed with combined therapy using ICG-
guided verteporfin photodynamic therapy plus three doses of
ranibizumab intravitreal injections 1 month apart [29].
Differentiating long-standing central serous chorioret-
inopathy (CSC) from nAMD can sometimes be difficult.
Chronic CSC patients often develop in old patients, with RPE
hyperplasia or atrophy, subretinal fluid and cystoid edema
in the OCT, and hyperfluorescence on fluorescein and ICG.
CSC can also be diagnosed with the help of enhanced depth
imaging on OCT. In addition, some patients presenting with
choroidal neovascularization have a missed background of
CSC and the etiology is erroneously ascribed to nAMD.
Atrophic changes in RPE are better seen with fundus autoflu-
orescence imaging and midphase. ICG showing bilateral
choroidal hyperpermeability can also help with the diagnosis.
In the OCT, subretinal fluid and hypertrophic outer retinal
changes are more common but intraretinal fluid is less
frequent. Choroidal thickness is also increased in CSC.
Chronic CSC is better treated with ICG-guided verteporfin
photodynamic therapy and ranibizumab may be also added
if CNV has also complicated the process [30].
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Those who gained vision in the initial 3 months but did
not maintain it must be considered “responders” although
the type of response is not so good. Some studies suggest
that patients treatedwith repeat intravitreal bevacizumab and
ranibizumab injections may demonstrate tachyphylaxis over
time [31]. When a patient does not respond adequately to the
drug of choice, the question arises whether a shift in therapy
to another VEGF inhibitor will be useful. Shifting patients
to ranibizumab after insufficient response to bevacizumab
has shown that most patients improved the anatomic status
of the macula on OCT (32% complete resolution of fluid
and 39% with partial response). However, the mean VA did
not change after shifting treatment, with individual changes
ranging from loss of 4 lines to gain of 2 lines [32]. When
patients are transitioned from bevacizumab, ranibizumab,
or both to aflibercept, 7% gained 2 lines or more and 85%
showed stable VA. Again, an improvement in the anatomic
outcomes was observed in the OCT after the change to
aflibercept with 5% showing complete resolution of baseline
exudative fluid and 49% showing partial resolution [33].
Finally, another group of responders are those who gain
and maintain visual improvement but need almost continu-
ous monthly injections, because there is always fluid in the
OCT during the follow-up visits. As previously mentioned,
in these cases we must rule out the possibility that the
fluid is not representing disease activity, like the residual
internal layers pseudocysts or the outer retinal tabulations
[27]. In addition, a follow-up visit may be scheduled two
weeks after the intravitreal injection in order to know if a
patient has an initial improvement of the fluid after treatment,
which then rapidly recurs with one month’s time [34]. In
these cases, treatment every two weeks, change of anti-VEGF
drug, or combined therapy with verteporfin and anti-VEGF
may be postulated [23, 33, 34]. Recently, some steroids and
slow-delivered steroid implants combined with anti-VEGF
have been postulated as an alternative option in eyes with
refractory nAMD [24, 35].
6. Criteria for Patient Follow-Up
Externalization
Interruption of the treatment can be considered in two ways:
temporary suspension of anti-VEGF injections whilst still
maintaining periodic controls or definite interruption of both
the injections and patient followup [36].
Just as in one way or another, the Pronto study has shown
that in certain cases the treatment with ranibizumab can be
suspended, at least temporarily without showing a loss of the
benefits obtained [12]. At the same time, it is observed that up
to 30% of the cases did not require additional treatment [36].
Meanwhile, the decision of suspending anti-VEGF treat-
ment in nAMD may result in very different situations. In
favourable situations, the treatment is interrupted due to the
long-term resolution of exudation and stability of vision; in
unfavourable situations, the interruption is fundamentally
due to the development of a fibrotic macular disciform scar,
chronic macular edema, or macular atrophy. The SEVEN-
UP study has shown that, approximately 7 years after ranibi-
zumab therapy, one-third of patients demonstrated good
visual outcomes, whereas another third had poor outcomes.
Active exudative disease was detected by spectral-domain
OCT in 68% of study eyes, and 46% were receiving ongoing
ocular anti-VEGF treatments. Macular atrophy was detected
by fundus autofluorescence in 98% of eyes and the area of
atrophy correlated significantly with poor visual outcome
[37].
For these reasons, we can conclude by affirming that
once the patient with nAMD is not a candidate to continue
with treatment, he/she should be sent to AMD outpatients
units, where a periodic followup can be carried out by a
specialist in macular disease who can perform the following
tests: measurement of VA, fundus examination, and macular
OCT [8]. At the same time, the aforementioned could be
complimented with the referral of certain patients to low
vision units (teams formed by ophthalmologists, opticians,
rehabilitation technicians, social workers, and psychologists),
thus increasing the use of units that are underused at present
[38]. All of this would contribute to reducing the healthcare
burden in hospitals and assuring a satisfactory control of
nAMD patients.
The creation of an AMD outpatient unit would therefore
signify a clear advance in assuring a better quality of life
for a chronic patient and reducing the healthcare burden of
the ophthalmologist services in an illness that has a strong
tendency for periodic visits (closer periods versus spaced out
checkups) and a growing demand due to demographic factors
[39].
7. Real-Life Practice Results of
Anti-VEGF in nAMD
Apart from clinical trials, several studies have explored differ-
ent regimens for the treatment of nAMDwith ranibizumab in
the “real world.”Most of them are based on a PRN scheme but
with more flexible criteria than in clinical trials to reduce the
burden of injections and follow-up visits [40]. However, over-
all results of these studies are not as good as those obtained
following the more rigid protocols of clinical trials. The
PRN regimens performed outside clinical trials have many
potential sources of noncompliance. Therefore, the risk of an
even worse outcome is higher and it remains controversial
whether initial good results can bemaintained over time [41].
Therefore, despite the ophthalmology community’s joy at
new developments in the treatment of nAMD in 2005 [4–7],
the inconvenience of monthly injections or at least monthly
followup remained. In addition, when analysing different
patient responses across clinical trials, individualization of
the treatment and the followup is needed. In the Lumiere
study performed in France, the mean VA gain at 12 months
was 3.2 ± 14.8 ETDRS letters [42]. Fewer than 40% of patients
received the recommended treatment of initial 3 monthly
injections, 50% patients had to wait more than 8 days for
the initial anti-VEGF treatment, and the average number of
injections was 5.1 during the 12-month period.
The retrospective pooled analysis of four European
registries (Wave/Germany; Helios/Netherlands; Helios/Bel-
gium; Sweden) within the LUMINOUS program has shown
that the mean improvement in ETDRS letters at 12 months
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was 0, 5.6, 2.5, and 1 with a mean number of 4.3, 5.5, 5.0, and
4,7 injections, respectively [43].
In theAURAmultinational study, themean improvement
from baseline in France was 0.8 letters and 0.1 at 1 year and
2 years, respectively [44]. In Germany, these figures were
−0.4 and −2.4, respectively. The mean number of injections
in years 1 and 2 was 4.4 and 1.9 in France and 4.2 and 1.1 in
Germany [44].
In Spain, a study has evaluated the degree of compliance
by Spanish retinal specialists with the Spanish Vitreoretinal
Society Guidelines for Management of AMD [45]. This
multicenter retrospective observational study included 346
patients. Adherence to SERV guidelines was high for the
diagnosis (96,8%), medium for initial treatment (84,4%),
and low for followup and retreatment (46,9%). In the first
year, follow-up visits were made every 2 months or more
frequently in 66.2% of patients. In the second year, followup
was even less frequent: every 3 months or more in 70.2% of
patients.
Another study in 12 sites across Spain, which included 208
patients followed for 24 months, has shown that the average
number of follow-up visits was 9 (5.4 and 3.6 during the first
and second year), the mean number of injections was 6.1 (4.5
and 1.6 during the first and second year), and the mean VA
gain was 2.4 ± 16.6 letters at 12 months and 3.1 ± 19.6 at 24
months [46].
Treatment with intravitreal anti-VEGF injections in real-
life practice produces, on average, poorer-than-expected
visual outcomes, probably due to fewer injections per year
and less than monthly monitoring. Recently, a Delphi study
to detect deficiencies in real-life treatment of nAMD was
performed in one hundred members of the Spanish Vit-
reoretinal Society [47]. Recommendations were developed
after analyzing the differences between the results and the
SERV guidelines recommendations. Consensus statements to
reduce the burden of the disease included the use of treat
and extend regimen and reducing the amount of diagnostic
tests during the loading phase and training technical staff to
perform these tests and reducing the time between relapse
detection and reinjection, as well as establishing patient
referral protocols to outside general ophthalmology clinics.
In conclusion, ranibizumab demonstrates a favourable
clinical effectiveness and dramatically improves outcomes in
nAMD, although some actionsmust be implemented in order
to enhance results in real-world practice. The positioning of
ranibizumab in nAMD will be defined more accurately in
the future, when data for existing and new therapies become
available.
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[38] J. Monés and F. Gómez-Ulla, Degeneración Macular Asociada a
la Edad, Prous Science, Barcelona, Spain, 2005.
[39] L. Arias, Actualización de Terapia Anti-VEGF en las Enfer-
medades de la Retina y Coroides, Elsevier España, 2010.
[40] L. Arias, I. Roman, C. Masuet-Aumatell et al., “One-year results
of a flexible regimen with ranibizumab therapy in macular
degeneration: relationship with the number of injections,”
Retina, vol. 31, no. 7, pp. 1261–1267, 2011.
8 Journal of Ophthalmology
[41] M. A. Singer, C. C. Awh, S. Sadda et al., “HORIZON: an
open-label extension trial of ranibizumab for choroidal neovas-
cularization secondary to age-related macular degeneration,”
Ophthalmology, vol. 119, no. 6, pp. 1175–1183, 2012.
[42] S. Y. Cohen,G.Mimoun,H.Oubrahamet al., “Changes in visual
acuity in patients with wet age-related macular degeneration
treated with intravitreal ranibizumab in daily clinical practice:
the lumiere study,” Retina, vol. 33, no. 3, pp. 474–481, 2013.
[43] P. Mitchel, “Ranibizumab in age-related macular degeneration:
a pooled analysis of European registries included in the LUMI-
NOUS program,” in Proceedings of the WOCMeeting, 2012.
[44] C. B. Hoyng and AURA Steering Committee, “Retrospective
analysis of the real world utilization of ranibizumab in AMD,”
in Proceedings of the World Congress on Controversies in Oph-
thalmology (COPHy ’13), Budapest, Hungary, April 2013.
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